November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Toni Choueiri: Our recent perspective on the next therapies in immuno-oncology trials
Nov 9, 2024, 10:21

Toni Choueiri: Our recent perspective on the next therapies in immuno-oncology trials

Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, posted on X about recent paper by him as co-author, titled “Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types” published on The Lancet.

Authors: Karl Semaana, Rashad Nawfala, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri

Toni Choueiri: Our recent perspective on the next therapies in immuno-oncology trials

Our recent perspective on the next/subsequent therapies in IO neoadj/adj trials. Data is often incomplete, access is variable, reporting is inconsistent and we share a consensus roadmap for clinical trials.”

Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.